Title: Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension
Abstract: Introduction: Combination therapy of the phosphodiesterase-type 5 (PDE-5) inhibitor sildenafil and the endothelin receptor antagonist (ERA) bosentan may cause drug interactions in patients with pulmonary arterial hypertension (PAH). The objective of this study was to analyse plasma drug concentrations in PAH-patients during bosentan-sildenafil combination treatment and its changes after transition from bosentan to macitentan.
Publication Year: 2016
Publication Date: 2016-02-09
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot